Unravelling the convoluted biological roles of type I interferons (IFN-Is) in infection and immunity: A way forward for therapeutics and vaccine design

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Wijesundara, Danushka Kumara ^a,c   Xi, Yang ^b   Ranasinghe, Charani ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Biology and Environment   (Australia)

Author keywords

Human immunodeficiency virus; IFN ; Interferon immunity; Type I interferons; Vaccine adjuvants

Indexed keywords

ADJUVANT; ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA4 INTERFERON; BETA INTERFERON; FALDAPREVIR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DRUG DESIGN; GENE EXPRESSION; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HERPES VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LEUKEMIA; LIFE CYCLE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; VIRAL CLEARANCE; VIRUS INFECTION;

EID: 84918829601     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00412     Document Type: Article

References (123)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc LondB BiolSci (1957) 147(927):258-67. Epub 1957/09/12. PubMed PMID: 13465720.
2. Adolf GR. Human interferon omega-a review. Mult Scler (1995) 1 Suppl l:S44-7. Epub 1995/01/01. PubMed PMID: 9345398.
3. Foster GR, Finter NB. Are all type I human interferons equivalent? J Viral Hepat (1998) 5(3): 143-52. Epub 1998/07/11. PubMed PMID: 9658366.
4. Kawamoto S, Oritani K, Asada H, Takahashi I, Ishikawa J, Yoshida H, et al. Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor \.J Virol (2003) 77(17):9622-31. Epub 2003/08/14. PubMed PMID: 12915574; PubMed Central PMCID: PMC187381.
5. Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, et al. IFN-tau: a novel subtype IIFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie (1998) 80(8-9):755-77. Epub 1998/12/29. doi: S0300-9084(99)80029-7 [pii]. PubMed PMID: 9865498.
6. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem (2001) 276(43):39765-71. Epub 2001/08/22. doi: 10.1074/jbc.M102502200 [doi] M102502200 [pii]. PubMedPMID: 11514542.
7. Oritani K, Medina KL, Tomiyama Y, Ishikawa J, Okajima Y, Ogawa M, et al. Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors. NatMed(2000) 6(6):659-66. Epub 2000/06/03. doi: 10.1038/76233 [doi]. PubMedPMID: 10835682.
8. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem (1987) 56:727-77. Epub 1987/01/01. doi: 10.1146/annurev.bi.56.070187.003455 [doi]. PubMedPMID: 2441659.
9. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem (1998) 67:227-64. Epub 1998/10/06. doi: 10.1146/annurev.biochem.67.1.227 [doi]. PubMedPMID: 9759489.
10. Sen GC. Viruses and interferons. Annu Rev Microbiol (2001) 55:255-81. Epub 2001/09/07. doi: 10.1146/annurev.micro.55.1.255 [doi] 55/1/255 [pii]. PubMed PMID: 11544356.
11. Karpov AV. Endogenous and exogenous interferons in HIV-infection. Eur J Med Res (2001) 6(12):507-24. Epub 2002/01/05. PubMed PMID: 11772539.
12. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2014) 14(l):36-49. Epub 2013/12/24. doi: nri3581 [pii] 10.1038/nri3581. PubMed PMID: 24362405.
13. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 284(5421): 1835-7. Epub 1999/06/12. PubMedPMID: 10364556.
14. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 5(12): 1219-26. Epub 2004/11/19. doi: nil 141 [pii] 10.1038/nill41 [doi]. PubMed PMID: 15549123.
15. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol (2010) 6(l):40-9. Epub 2010/01/05. doi: nrrheum.2009.237 [pii] 10.1038/nrrheum.2009.237. PubMedPMID: 20046205; PubMed Central PMCID: PMC3622245.
16. Dhondt KP, Mathieu C, Chalons M, Reynaud JM, Vallve A, Raoul H, et al. Type I interferon signaling protects mice from lethal henipavirus infection. J Infect Dis (2013) 207(1):142-51. Epub 2012/10/24. doi: jis653 [pii] 10.1093/infdis/jis653. PubMed PMID: 23089589.
17. Gerlach N, Schimmer S, Weiss S, Kalinke U, Dittmer U. Effects of type I interferons on Friend retrovirus infection. J Virol (2006) 80(7):3438-44. Epub 2006/03/16. doi: 80/7/3438 [pii] 10.1128/JVI.80.7.3438-3444.2006. PubMedPMID: 16537611; PubMed Central PMCID: PMC1440373.
18. Lobigs M, Mullbacher A, Wang Y, Pavy M, Lee E. Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. J Gen Virol (2003) 84(Pt 3):567-72. Epub 2003/02/27. PubMed PMID: 12604807.
19. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 340(6129):207-ll. Epub 2013/04/13. doi: 340/6129/207 [pii] 10.1126/science. 1235214. PubMed PMID: 23580529; PubMed Central PMCID: PMC3640797.
20. Dowall SD, Findlay-Wilson S, Rayner E, Pearson G, Pickersgill J, Rule A, et al. Hazara virus infection is lethal for adult type I interferon receptor-knockout mice and may act as a surrogate for infection with the human-pathogenic Crimean-Congo hemorrhagic fever virus. J Gen Virol (2012) 93(Pt 3):560-4. Epub 2011/11/18. doi: vir.0.038455-0 [pii] 10.1099/vir.0.038455-0. PubMedPMID: 22090213.
21. Zust R, Toh YX, Valdes I, Cerny D, Heinrich J, Hermida L, et al. Type IIFN signals in macrophages and dendritic cells control dengue vims infection: implications for a new mouse model to test dengue vaccines. J Virol (2014). Epub 2014/04/18. doi: JVI.03827-13 [pii] 10.1128/JVI.03827-13. PubMedPMID: 24741106.
22. Gortizka M, Durant LR, Pereira C, Salek-Ardakani S, Openshaw PJM, et al. Interferon-a/p receptor signaling amplifies early pro-inflammatory 2 cytokine production in the lung during Respiratory Syncytial Virus 3 infection, J Virol (2014). In press. doi:10.1128/JVI.00333-14
23. Carrero JA. Confounding roles for type I interferons during bacterial and viral pathogenesis. Int Immunol (2013) 25(12):663-9. Epub 2013/10/26. doi: dxt050 [pii] 10.1093/intimm/dxt050. PubMed PMID: 24158954; PubMed Central PMCID: PMC3839063.
24. Alsharifi M, Regner M, Blanden R, Lobigs M, Lee E, Koskinen A, et al. Exhaustion of type I interferon response following an acute viral infection. J Immunol (2006) 177(5):3235-41. Epub 2006/08/22. doi: 177/5/3235 [pii]. PubMedPMID: 16920963.
25. Kamga I, Kahi S, Develioglu L, Lichtner M, Maranon C, Deveau C, et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis (2005) 192(2):303-10. Epub 2005/06/18. doi: JID34052 [pii] 10.1086/430931. PubMedPMID: 15962225.
26. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, Arthos J, et al. HIV-1 gpl20 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci USA (2007) 104(9):3396-401. Epub 2007/03/16. doi: 0611353104 [pii] 10.1073/pnas.0611353104. PubMed PMID: 17360657; Pub Med Central PMCID: PMC1805537.
27. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature (2013) 503(7476):402-5. Epub 2013/11/08. doi: naturel2769 [pii] 10.1038/naturel2769. PubMed PMID: 24196705; PubMed Central PMCID: PMC3928559.
28. Fitzgerald-Bocarsly P, Jacobs ES. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. JLeukoc Biol (2010) 87(4):609-20. Epub 2010/02/11. doi: jlb.0909635 [pii] 10.1189/jlb.0909635. PubMedPMID: 20145197; PubMed Central PMCID: PMC2858309.
29. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood (2001) 98(4):906-12. Epub 2001/08/09. PubMedPMID: 11493432.
30. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, et al. Reduced blood CD123+ (lymphoid) and CD1 lc+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood (2001) 98(10):3016-21. Epub 2001/11/08. PubMed PMID: 11698285.
31. Schmidt B, Scott I, Whitmore RG, Foster H, Fujimura S, Schmitz J, et al. Low-level HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell death after PDC maturation. Virology (2004) 329(2):280-8. Epub 2004/11/03. doi: S0042-6822(04)00555-0 [pii] 10.1016/j.virol.2004.08.016. PubMedPMID: 15518808.
32. Bruel T, Dupuy S, Demoulins T, Rogez-Kreuz C, Dutrieux J, Corneau A, et al. Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIVinfected cynomolgus macaques. PLoS Pathog (2014) 10(l):el003915. Epub 2014/02/06. doi: 10.1371/journal.ppat.l003915 PPATHOGENS-D-13-00268 [pii]. PubMed PMID: 24497833; PubMed Central PMCID: PMC3907389.
33. Guha D, Ayyavoo V. Innate Immune Evasion Strategies by Human Immunodeficiency Vims Type l.ISRN AIDS (2013) 2013:954806. Epub 2013/09/21. doi: 10.1155/2013/954806. PubMedPMID: 24052891; PubMed Central PMCID: PMC3767209.
34. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA (2009) 106(22):9010-5. Epub 2009/05/20. doi: 0901329106 [pii] 10.1073/pnas.0901329106. PubMedPMID: 19451644; PubMed Central PMCID: PMC2690021.
35. de la Maza LM, EM Peterson, JM Goebel, CW Fennie and CW Czarniecki. Interferon-induced inhibition of Chlamydia trachomatis: dissociation from antiviral and antiproliferative effects. Infect Immun 1985; 47: 719-22.
36. Buss C, B Opitz, AC Hocke, J Lippmann, V van Laak, S Hippenstiel, et al. Essential role of mitochondrial antiviral signaling, IFN regulatory factor (IRF)3, and IRF7 in Chlamydophila pneumoniae-mediated IFN-beta response and control of bacterial replication in human endothelial cells. J Immunol 2010; 184: 3072-8.
37. Desvignes L, AJ Wolf and JD Ernst. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol 2012; 188: 6205-15.
38. LeMessurier KS, H Hacker, L Chi, E Tuomanen and V Redecke. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog 2013; 9: el003727.
39. Zhang Y, Thai V, McCabe A, Jones M, MacNamara KC. Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis. Infect Immun (2014) 82(4): 1698-709. Epub 2014/02/05. doi: IAI.01564-13 [pii] 10.1128/IAI.01564-13. PubMed PMID: 24491580; PubMed Central PMCID: PMC3993392.
40. Nagarajan UM, Prantner D, Sikes JD, Andrews CW, Jr., Goodwin AM, Nagarajan S, et al. Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect Immun (2008) 76(10):4642-8. Epub 2008/07/30. doi: IAI.00629-08 [pii] 10.1128/IAI.00629-08. PubMedPMID: 18663004; PubMed Central PMCID: PMC2546839.
41. Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med(2004) 200(4):527-33. Epub 2004/08/11. doi: 10.1084/jem.20040976 jem.20040976 [pii]. PubMed PMID: 15302899; PubMed Central PMCID: PMC2211930.
42. Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog (2014) 10(1):el003861. Epub 2014/01/07. doi: 10.1371/journal.ppat. 1003861 PPATHOGENS-D-13-01967 [pii]. PubMedPMID: 24391507; PubMed Central PMCID: PMC3879373.
43. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ, et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res (2005) 25(ll):694-701. Epub 2005/12/02. doi: 10.1089/jir.2005.25.694. PubMed PMID: 16318583.
44. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science (2013) 339(6126): 1448-53. Epub 2013/03/02. doi: science. 1233665 [pii] 10.1126/science. 1233665. PubMedPMID: 23449998; PubMed Central PMCID: PMC3653587.
45. Henry T, Kirimanjeswara GS, Ruby T, Jones JW, Peng K, Perret M, et al. Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol (2010) 184(7):3755-67. Epub 2010/02/24. doi: jimmunol.0902065 [pii] 10.4049/jimmunol.0902065. PubMedPMID: 20176744; PubMed Central PMCID: PMC2879132.
46. Navarini AA, Recher M, Lang KS, Georgiev P, Meury S, Bergthaler A, et al. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Natl Acad Sci USA (2006) 103(42):15535-9. Epub 2006/10/13. doi: 0607325103 [pii] 10.1073/pnas.0607325103. PubMedPMID: 17030789; PubMed Central PMCID: PMC1622858.
47. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol (2012) 86(22): 12304-12. Epub 2012/09/07. doi: JVI.01269-12 [pii] 10.1128/JVI.01269-12. PubMedPMID: 22951826; PubMed Central PMCID: PMC3486468.
48. Trinchieri G. Type I interferon: friend or foe? JExpMed (2010) 207(10):2053-63. Epub 2010/09/15. doi: jem.20101664 [pii] 10.1084/jem.20101664. PubMedPMID: 20837696; PubMed Central PMCID: PMC2947062.
49. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TREVI22. PLoS Pathog (2008) 4(2):el000007. Epub 2008/04/05. doi: 10.1371/journal.ppat. 1000007 [doi]. PubMedPMID: 18389079; PubMed Central PMCID: PMC2279259.
50. Sakuma R, Noser JA, Ohmine S, Ikeda Y. Rhesus monkey TREVI5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med (2007) 13(5):631-5. Epub 2007/04/17. doi: nml562 [pii] 10.1038/nml562 [doi]. PubMedPMID: 17435772.
51. Sokolskaja E, Luban J. Cyclophilin, TREVI5, and innate immunity to HIV-1. Curr Opin Microbiol (2006) 9(4):404-8. Epub 2006/07/04. doi: S1369-5274(06)00094-4 [pii] 10.1016/j.mib.2006.06.011 [doi]. PubMed PMID: 16815734.
52. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol (2005) 3(10):799-808. Epub 2005/09/22. doi: nrmicrol248 [pii] 10.1038/nrmicrol248 [doi]. PubMedPMID: 16175175.
53. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci USA (2006) 103(5): 1440-5. Epub 2006/01/26. doi: 0510518103 [pii] 10.1073/pnas.0510518103 [doi]. PubMedPMID: 16434471; PubMed Central PMCID: PMC1360585.
54. Boasso A, Royle CM, Doumazos S, Aquino VN, Biasin M, Piacentini L, et al. Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis. Blood (2011) 118(19):5152-62. Epub 2011/09/21. doi: blood-2011-03-344218 [pii] 10.1182/blood-2011-03-344218. PubMed PMID: 21931112; PubMed Central PMCID: PMC3217402.
55. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 119(12):3556-72. Epub 2009/12/05. doi: 40115 [pii] 10.1172/JCI40115. PubMed PMID: 19959874; PubMed Central PMCID: PMC2786806.
56. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med (1999) 189(5):821-9. Epub 1999/03/02. PubMed PMID: 10049946; PubMed Central PMCID: PMC2192946.
57. Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood (2001) 98(10):3022-9. Epub 2001/11/08. PubMed PMID: 11698286.
58. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 99(9):3263-71. Epub 2002/04/20. PubMed PMID: 11964292.
59. Welsh RM, Bahl K, Marshall HD, Urban SL. Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog (2012) 8(l):el002352. Epub 2012/01/14. doi: 10.1371/journal.ppat. 1002352 PPATHOGENS-D-11-01797 [pii]. PubMed PMID: 22241987; PubMed Central PMCID: PMC3252364.
60. Simmons DP, Wearsch PA, Canaday DH, Meyerson HJ, Liu YC, Wang Y, et al. Type IIFN drives a distinctive dendritic cell maturation phenotype that allows continued class IIMHC synthesis and antigen processing. J Immunol (2012) 188(7):3116-26. Epub 2012/03/01. doi: jimmunol. 1101313 [pii] 10.4049/jimmunol. 1101313. PubMed PMID: 22371391; PubMed Central PMCID: PMC3311734.
61. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 208(10):1989-2003. Epub 2011/09/21. doi: jem.20101158 [pii] 10.1084/jem.20101158. PubMed PMID: 21930769; PubMed Central PMCID: PMC3182061.
62. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 208(10):1989-2003. Epub 2011/09/21. doi: jem.20101158 [pii] 10.1084/jem.20101158. PubMed PMID: 21930769; PubMed Central PMCID: PMC3182061.
63. Cai G, Kami A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol (2004) 230(2):89-98. Epub 2004/12/16. doi: S0008-8749(04)00169-8 [pii] 10.1016/j.cellimm.2004.09.004. PubMed PMID: 15598424.
64. Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol (2002) 14(4):411-9. Epub 2002/04/06. PubMed PMID: 11934877.
65. Alsharifi M, Lobigs M, Regner M, Lee E, Koskinen A, Mullbacher A. Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection. J Immunol (2005) 175(7):4635-40. Epub 2005/09/24. doi: 175/7/4635 [pii]. PubMed PMID: 16177109.
66. Wijesundara DK, Kumar S, Alsharifi M, Mullbacher A, Regner M. Antigen-specific activation thresholds of CD8+ T cells are independent of IFN-I-mediated partial lymphocyte activation. Int Immunol (2010) 22(9):757-67. Epub 2010/08/05. doi: dxqO64 [pii] 10.1093/intimm/dxq064. PubMed PMID: 20682547.
67. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 440(7083):540-4. Epub 2006/03/10. doi: nature04606 [pii] 10.1038/nature04606. PubMed PMID: 16525420.
68. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol (1999) 162(6):3256-62. Epub 1999/03/27. PubMed PMID: 10092777.
69. Curtsinger JM, Gerner MY, Lins DC, Mescher MF. Signal 3 availability limits the CD8 T cell response to a solid tumor. J immunol (2007) 178(11):6752-60. Epub 2007/05/22. doi: 178/11/6752 [pii]. PubMedPMID: 17513722.
70. Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med (2014) 211(5):961-74. Epub 2014/04/09. doi: jem.20131556 [pii] 10.1084/jem.20131556. PubMedPMID: 24711580; PubMed Central PMCID: PMC4010906.
71. Starbeck-Miller GR, Xue HH, Harty JT. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. JExpMed (2014) 211(1): 105-20. Epub 2013/12/25. doi: jem.20130901 [pii] 10.1084/jem.20130901. PubMed PMID: 24367005; PubMed Central PMCID: PMC3 892973.
72. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med (1999) 189(3):521-30. Epub 1999/02/02. PubMedPMID: 9927514; PubMed Central PMCID: PMC2192920.
73. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med (2005) 202(5):637-50. Epub 2005/09/01. doi:jem.20050821 [pii] 10.1084/jem.20050821. PubMedPMID: 16129706; PubMed Central PMCID: PMC2212878.
74. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med (1993) 178(5):1655-63. Epub 1993/11/01. PubMedPMID: 8228812; PubMed Central PMCID: PMC2191249.
75. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity (2010) 33(l):96-105. Epub 2010/07/20. doi: SI074-7613(10)00242-6 [pii] 10.1016/j.immuni.2010.06.016. PubMed PMID: 20637658; PubMed Central PMCID: PMC2908370.
76. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type IIFN. J Immunol (2006) 176(4):2074-8. Epub 2006/02/04. doi: 176/4/2074 [pii]. PubMedPMID: 16455962.
77. Zhang L, Yuan S, Cheng G, Guo B. Type I IFN promotes IL-10 production from T cells to suppress Thl7 cells and Thl7-associated autoimmune inflammation. PLoS One (2011) 6(12):e28432. Epub 2011/12/14. doi: 10.1371/journal.pone.0028432 PONE-D-11-07676 [pii]. PubMed PMID: 22163016; PubMed Central PMCID: PMC3232207.
78. Stewart CA, Metheny H, Iida N, Smith L, Hanson M, Steinhagen F, et al. Interferon-dependent IL-10 production by Tregs limits tumor Thl7 inflammation. J ClinInvest (2013) 123(11):4859-74. Epub 2013/11/13. doi: 65180 [pii] 10.1172/JCI65180. PubMed PMID: 24216477; PubMed Central PMCID: PMC3 809773.
79. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 16(4):452-9. Epub 2010/03/09. doi: nm.2106 [pii] 10.1038/nm.2106. PubMedPMID: 20208540.
80. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439(7077):682-7. Epub 2005/12/31. doi: natureO4444 [pii] 10.1038/nature04444. PubMedPMID: 16382236.
81. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 186(5):2772-9. Epub 2011/01/26. doi: jimmunol. 1003208 [pii] 10.4049/jimmunol. 1003208. PubMed PMID: 21263073.
82. Lin L, Hou J, Ma F, Wang P, Liu X, Li N, et al. Type IIFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol (2013) 191(7):3896-904. Epub 2013/08/28. doi: jimmunol. 1203450 [pii] 10.4049/jimmunol. 1203450. PubMed PMID: 23980205.
83. Fraietta JA, Mueller YM, Yang G, Boesteanu AC, Gracias DT, Do DH, et al. Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog (2013) 9(10):el003658. Epub 2013/10/17. doi: 10.1371/journal.ppat. 1003658 [doi] PPATHOGENS-D-13-00775 [pii]. PubMed PMID: 24130482; PubMed Central PMCID: PMC3795023.
84. Rubinstein M, S Rubinstein, PC Familletti, MS Gross, RS Miller, AA Waldman, et al. Human leukocyte interferon purified to homogeneity. Science 1978; 202: 1289-90.
85. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282: 20047-51.
86. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 352(26):2682-95. Epub 2005/07/01. doi: 352/26/2682 [pii] 10.1056/NEJMoa043470. PubMed PMID: 15987917.
87. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 351(12): 1206-17. Epub 2004/09/17. doi: 10.1056/NEJMoa040431351/12/1206 [pii]. PubMed PMID: 15371578.
88. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2013) 207(2):213-22. Epub 2012/10/30. doi: jis663 [pii] 10.1093/infdis/jis663. PubMed PMID: 23105144; PubMed Central PMCID: PMC3532820.
89. Jones BR, Coster DJ, Falcon MG, Cantell K. Topical therapy of ulcerative herpetic keratitis with human interferon. Lancet (1976) 2(7977): 128. Epub 1976/07/17. PubMed PMID: 59189.
90. Lui SF, Ali AA, Grundy JE, Fernando ON, Griffiths PD, Sweny P. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant (1992) 7(12): 1230-7. Epub 1992/01/01. PubMed PMID: 1337164.
91. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 298(18):981-7. Epub 1978/05/04. doi: 10.1056/NEJM197805042981801 [doi]. PubMed PMID: 347294.
92. Pazin GJ, Armstrong JA, Lam MT, Tarr GC, Jannetta PJ, Ho M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med(1979) 301(5):225-30. Epub 1979/08/02. doi: 10.1056/NEJM197908023010501 [doi]. PubMed PMID: 221812.
93. Pazin GJ, Armstrong JA, Lam MT, Tarr GC, Jannetta PJ, Ho M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. NEnglJMed(1979) 301(5):225-30. Epub 1979/08/02. doi: 10.1056/NEJM197908023010501 [doi]. PubMed PMID: 221812.
94. Deunas L, Alcantud V, Alvarez F, Arteaga J, Benitez A, Bopuza M, et al. Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme. J Laryngol Otol (1997) 111(2): 134-40. Epub 1997/02/01. PubMed PMID: 9102438.
95. Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. N Engl J Med (1986) 315(17): 1059-64. Epub 1986/10/23. doi: 10.1056/NEJM198610233151704 [doi]. PubMed PMID: 3531860.
96. Haglund S, Lundquist PG, Cantell K, Strander H. Interferon therapy in juvenile laryngeal papillomatosis. Arch Otolaryngol (1981) 107(6):327-32. Epub 1981/06/01. PubMed PMID: 6164359.
97. Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med (1988) 319(7):401- Epub 1988/08/18. doi: 10.1056/NEJM198808183190704 [doi]. PubMed PMID: 3398891.
98. Lace MJ, Anson JR, Klingelhutz AJ, Harada H, Taniguchi T, Bossier AD, et al. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-l. Carcinogenesis (2009) 30(8): 1336-44. Epub 2009/06/23. doi: bgpl50 [pii] 10.1093/carcin/bgpl50 [doi]. PubMed PMID: 19541854.
99. Pazin GJ, Ho M, Haverkos HW, Armstrong JA, Breinig MC, Wechsler HL, et al. Effects of interferon-alpha on human warts. J Interferon Res (1982) 2(2):235-43. Epub 1982/01/01. PubMed PMID: 7119508.
100. Week PK, Buddin DA, Whisnant JK. Interferons in the treatment of genital human papillomavirus infections. Am JMed (1988) 85(2A): 159-64. Epub 1988/08/29. PubMed PMID: 3044081.
101. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 339(21): 1485-92. Epub 1998/11/20. doi: 10.1056/NEJM199811193392101. PubMed PMID: 9819446.
102. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352(9138): 1426-32. Epub 1998/11/10. doi: S0140673698071244 [pii]. PubMed PMID: 9807989.
103. Baker DE. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord (2003) 3(2):93-109. Epub 2003/05/31. PubMed PMID: 12776006.
104. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatmentnaive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology (2013) 57(6):2143-54. Epub 2013/01/30. doi: 10.1002/hep.26276. PubMed PMID: 23359516.
105. Takagi H, Hoshino T, Naganuma A, Koitabashi E, Uehara S, Sakamoto N, et al. Drug induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in patient with double positive for HBV and HCV. Hepatogastroenterology (2013) 60(127): 1557-60. Epub 2014/03/15. PubMed PMID: 24627926.
106. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 98(10):3074-81. Epub 2001/11/08. PubMed PMID: 11698293.
107. Li YF, Wang QZ, Zhang TT, Li L, Wang JP, Ding GF, et al. Low dose of interferon-alpha improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study. Oncol Lett (2014) 7(1): 125-30. Epub 2013/12/19. doi: 10.3892/ol.2013.1653 [doi] ol-07-01-0125 [pii]. PubMed PMID: 24348833; PubMed Central PMCID: PMC3861530.
108. Machado FA, Abdalla DR, Montes L, Etchebehere RM, Michelin MA, Murta EF. An evaluation of immune system cell infiltrate in the cervical stroma of patients with grade III cervical intraepithelial neoplasia after treatment with intralesional alpha-2B interferon. Eur JGynaecol Oncol (2014) 35(l):20-5. Epub 2014/03/25 06:00. PubMed PMID: 24654456.
109. Bracci L, Canini I, Venditti M, Spada M, Puzelli S, Donatelli I, et al. Type IIFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine (2006) 24 Suppl 2:S2-56-7. Epub 2006/07/11. PubMed PMID: 16823927.
110. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol (2002) 169(l):375-83. Epub 2002/06/22. PubMed PMID: 12077267.
111. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol (2002) 169(l):375-83. Epub 2002/06/22. PubMed PMID: 12077267.
112. Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine (2005) 23(23):2994-3004. Epub 2005/04/07. doi: S0264-410X(04)00940-5 [pii] 10.1016/j.vaccine.2004.12.006 [doi]. PubMed PMID: 15811645.
113. Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol (2008) 180(11):7158-66. Epub 2008/05/21. doi: 180/11/7158 [pii]. PubMed PMID: 18490714.
114. Xi Y, Day SL, Jackson RJ, Ranasinghe C. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol (2012) 5(6):610-22. Epub 2012/05/24. doi: mi201235 [pii] 10.1038/mi.2012.35 [doi]. PubMed PMID: 22617838; PubMed Central PMCID: PMC3481022.
115. Roisman LC, J Piehler, JY Trosset, HA Scheraga and G Schreiber. Structure of the interferon-receptor complex determined by distance constraints from doublemutant cycles and flexible docking. Proc Natl Acad Sci U S A 2001; 98: 13231-6.
116. Lamken P, S Lata, M Gavutis and J Piehler. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol 2004; 341: 303-18.
117. Jaks E, M Gavutis, G Uze, J Martal and J Piehler. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007; 366: 525-39.
118. Banchereau J and V Pascual. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-92.
119. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011; 116: 227-37.
120. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. JExpMed (2006) 203(l):41-6. Epub 2006/01/19. doi: jem.20051512 [pii] 10.1084/jem.20051512 [doi]. PubMed PMID: 16418394; PubMed Central PMCID: PMC2118075.
121. Fung KY, Mangan NE, Cumming H, Horvat JC, May All JR, Stifter SA, et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science (2013) 339(6123): 1088-92. Epub 2013/03/02. doi: 339/6123/1088 [pii] 10.1126/science. 1233321. PubMedPMID: 23449591; PubMed Central PMCID:PMC3617553.
122. Hermant P, Francius C, Clotman F, Michiels T. IFN-epsilon is constitutively expressed by cells of the reproductive tract and is inefficiently secreted by fibroblasts and cell lines. PLoS One (2013) 8(8):e71320. Epub 2013/08/21. doi: 10.1371/journal.pone.0071320PONE-D-13-22339 [pii]. PubMedPMID: 23951133; PubMed Central PMCID: PMC3739789.
123. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 280(5362):427-31. Epub 1998/05/09. PubMedPMID: 9545219.